EPISODE · Jun 13, 2025 · 34 MIN
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
A conversation with Ben Fairfax about the recent article: CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade. This episode discusses Milotay, G., Little, M., Watson, R.A. et al. CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade. Nat Med (2025). https://doi.org/10.1038/s41591-025-03647-1.
Embed this episode
Ready to play
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
0:00
34:58
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of To Immunity and Beyond?
This episode is 34 minutes long.
When was this To Immunity and Beyond episode published?
This episode was published on June 13, 2025.
Can I download this To Immunity and Beyond episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!